Quantcast

Lowering plaque protein in blood may offer treatment for Alzheimer’s

Agents that alter blood levels of beta-amyloid protein in mouse models of Alzheimer’s disease represent a potential approach to treating the illness in humans that may be safer than the vaccine method of therapy, researchers report in a new study. Beta-amyloid protein is a component of the amyloid plaques that accumulate in the brains of people with Alzheimer?’s disease. Beta-amyloid is viewed by many researchers and clinicians as the underlying cause of the degeneration and dementia that characterize the illness. Alzheimer’s disease is a progressive, degenerative brain disease and the most common form of dementia. There is no cure.